IL-40 levels in treatment-naive and methotrexate-treated rheumatoid arthritis patients.

IF 1 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Turkish Journal of Medical Sciences Pub Date : 2025-03-24 eCollection Date: 2025-01-01 DOI:10.55730/1300-0144.6013

Hamdi Oğuzman, Mete Pekdiker

{"title":"IL-40 levels in treatment-naive and methotrexate-treated rheumatoid arthritis patients.","authors":"Hamdi Oğuzman, Mete Pekdiker","doi":"10.55730/1300-0144.6013","DOIUrl":null,"url":null,"abstract":"Background/aim: Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by persistent inflammation and progressive damage to the joints. In this study, it was aimed to explore the role of interleukin (IL)-40, a newly discovered cytokine, in the pathogenesis of RA. We also aimed to investigate the relationship between IL-40 and other cytokines such as IL-4, transforming growth factor (TGF)-β1 and tumor necrosis factor (TNF)-α.Materials and methods: This single-center, cross-sectional study included 87 participants divided into three groups: healthy controls (n = 29), newly diagnosed RA patients (n = 29), and RA patients with remission under methotrexate (MTX) monotherapy (n = 29). Serum samples were collected and analyzed for IL-40, IL-4, TGF-β1 and TNF-α levels using ELISA. Disease activity score, presence of autoantibodies and other relevant clinical data were obtained from hospital electronic records.Results: Elevated IL-40 levels were found in the newly diagnosed RA patients and in those treated with MTX compared to the control group (p < 0.001). Logistic regression analysis confirmed IL-40 as an independent predictor in the newly diagnosed (OR = 1.023, 95% CI: 1.010-1.035, p = 0.002) and RA MTX-treated patients (OR = 1.023, 95% CI: 1.011-1.036, p < 0.001). IL-40 levels remained unchanged in the newly diagnosed RA group compared to RA patients in the MTX-treated group. In the dual-seropositive patients, TGF-β1 was lower in the MTX-treated RA patients compared to the naive patients (p = 0.013) and in the dual-seronegative patients, TNF-α was decreased in the MTX-treated RA patients in comparison to naive patients (p = 0.043).Conclusion: This study demonstrates that IL-40 levels are elevated in RA patients and highlights its potential role in RA. The fact that IL-40 levels did not change despite the antiinflammatory effects of MTX suggests that IL-40 is involved in immunological pathways that are less responsive to treatment.","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"658-665"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270298/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55730/1300-0144.6013","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by persistent inflammation and progressive damage to the joints. In this study, it was aimed to explore the role of interleukin (IL)-40, a newly discovered cytokine, in the pathogenesis of RA. We also aimed to investigate the relationship between IL-40 and other cytokines such as IL-4, transforming growth factor (TGF)-β1 and tumor necrosis factor (TNF)-α.

Materials and methods: This single-center, cross-sectional study included 87 participants divided into three groups: healthy controls (n = 29), newly diagnosed RA patients (n = 29), and RA patients with remission under methotrexate (MTX) monotherapy (n = 29). Serum samples were collected and analyzed for IL-40, IL-4, TGF-β1 and TNF-α levels using ELISA. Disease activity score, presence of autoantibodies and other relevant clinical data were obtained from hospital electronic records.

Results: Elevated IL-40 levels were found in the newly diagnosed RA patients and in those treated with MTX compared to the control group (p < 0.001). Logistic regression analysis confirmed IL-40 as an independent predictor in the newly diagnosed (OR = 1.023, 95% CI: 1.010-1.035, p = 0.002) and RA MTX-treated patients (OR = 1.023, 95% CI: 1.011-1.036, p < 0.001). IL-40 levels remained unchanged in the newly diagnosed RA group compared to RA patients in the MTX-treated group. In the dual-seropositive patients, TGF-β1 was lower in the MTX-treated RA patients compared to the naive patients (p = 0.013) and in the dual-seronegative patients, TNF-α was decreased in the MTX-treated RA patients in comparison to naive patients (p = 0.043).

Conclusion: This study demonstrates that IL-40 levels are elevated in RA patients and highlights its potential role in RA. The fact that IL-40 levels did not change despite the antiinflammatory effects of MTX suggests that IL-40 is involved in immunological pathways that are less responsive to treatment.

查看原文本刊更多论文

未接受治疗和甲氨蝶呤治疗的类风湿关节炎患者IL-40水平

背景/目的：类风湿性关节炎（RA）是一种自身免疫性疾病，其特征是关节持续炎症和进行性损伤。本研究旨在探讨新发现的细胞因子白介素(IL)-40在RA发病中的作用。我们还旨在探讨IL-40与其他细胞因子如IL-4、转化生长因子(TGF)-β1、肿瘤坏死因子(TNF)-α的关系。材料和方法：这项单中心横断面研究包括87名参与者，分为三组：健康对照组（n = 29），新诊断的RA患者（n = 29）和甲氨蝶呤（MTX）单药治疗缓解的RA患者（n = 29）。采集血清样本，采用ELISA法检测IL-40、IL-4、TGF-β1、TNF-α水平。疾病活动度评分、自身抗体的存在及其他相关临床数据从医院电子记录中获取。结果：与对照组相比，新诊断的RA患者和接受MTX治疗的患者IL-40水平升高（p < 0.001）。Logistic回归分析证实IL-40是新诊断（OR = 1.023, 95% CI: 1.010-1.035, p = 0.002）和接受mtx治疗的RA患者（OR = 1.023, 95% CI: 1.011-1.036, p < 0.001）的独立预测因子。与mtx治疗组的RA患者相比，新诊断RA组的IL-40水平保持不变。在双血清阳性患者中，mtx治疗的RA患者TGF-β1低于初发患者（p = 0.013）；在双血清阴性患者中，mtx治疗的RA患者TNF-α低于初发患者（p = 0.043）。结论：本研究表明IL-40水平在RA患者中升高，并强调其在RA中的潜在作用。尽管MTX具有抗炎作用，但IL-40水平并未发生变化，这一事实表明IL-40参与了对治疗反应较弱的免疫途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Medical Sciences 医学-医学：内科

CiteScore

4.60

自引率

4.30%

发文量

143

审稿时长

3-8 weeks

期刊介绍： Turkish Journal of Medical sciences is a peer-reviewed comprehensive resource that provides critical up-to-date information on the broad spectrum of general medical sciences. The Journal intended to publish original medical scientific papers regarding the priority based on the prominence, significance, and timeliness of the findings. However since the audience of the Journal is not limited to any subspeciality in a wide variety of medical disciplines, the papers focusing on the technical details of a given medical subspeciality may not be evaluated for publication.